{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:17:23Z","timestamp":1783077443201,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030728","name":"Debiopharm","doi-asserted-by":"publisher","award":["WO\/2023\/198884"],"award-info":[{"award-number":["WO\/2023\/198884"]}],"id":[{"id":"10.13039\/100030728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102749","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:10:43Z","timestamp":1776697843000},"page":"102749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS"],"prefix":"10.1016","volume":"7","author":[{"given":"L\u00e9o","family":"Marx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Hue-Perron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Monjardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Vigano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Chardonnens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esthela","family":"Artiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Roubaudi-Fraschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Wuttke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karilyn","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ivanschitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102749_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102749_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of Acute Myeloid Leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.xcrm.2026.102749_bib3","unstructured":"SEER database: Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). 2017 https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"10.1016\/j.xcrm.2026.102749_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2026.102749_bib5","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102749_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102749_bib7","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3324\/haematol.13405","article-title":"Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts","volume":"93","author":"Mufti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102749_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrm1736","article-title":"Tetraspanin functions and associated microdomains","volume":"6","author":"Hemler","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102749_bib9","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.4049\/jimmunol.1402414","article-title":"Tetraspanin CD37 Regulates beta2 Integrin-Mediated Adhesion and Migration in Neutrophils","volume":"195","author":"Wee","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102749_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4049\/immunohorizons.2400014","article-title":"Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions","volume":"8","author":"Hoeger","year":"2024","journal-title":"Immunohorizons"},{"key":"10.1016\/j.xcrm.2026.102749_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102749_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249531","article-title":"CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies","volume":"21","author":"Bobrowicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102749_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphys.2015.00091","article-title":"Tetraspanins as therapeutic targets in hematological malignancy: a concise review","volume":"6","author":"Beckwith","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.xcrm.2026.102749_bib14","article-title":"CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia","volume":"5","author":"Caulier","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102749_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2024013590","article-title":"CD37 in acute myeloid leukemia: a novel surface target for drug delivery","volume":"9","author":"Jeremy","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102749_bib16","article-title":"CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.xcrm.2026.102749_bib17","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B\/T-Cell Malignancies and AML: A New Role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102749_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102476","article-title":"CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia","volume":"20","author":"Lu","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102749_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2300855","article-title":"A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia","volume":"29","author":"Fang","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.xcrm.2026.102749_bib20","first-page":"115","article-title":"Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia","volume":"15","author":"Zhang","year":"2025","journal-title":"Blood Lymphat. Cancer."},{"key":"10.1016\/j.xcrm.2026.102749_bib21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102749_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102749_bib23","unstructured":"US Food and Drug Administration (2017). MYLOTARGTM (gemtuzumab ozogamicin) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf."},{"key":"10.1016\/j.xcrm.2026.102749_bib24","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","article-title":"Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability","volume":"9","author":"Oroudjev","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102749_bib25","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102749_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2021-145102","article-title":"Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study","volume":"138","author":"Levy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102749_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.102749_bib28","unstructured":"Marx, L., Pantin, M.L.C., and Adam, A.S.D. (2023) Ligand-drug-conjugates with Improvd Pharmacokinetic and Drug Release Properties."},{"key":"10.1016\/j.xcrm.2026.102749_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102749_bib30","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/leu.2014.32","article-title":"The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model","volume":"28","author":"Beckwith","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102749_bib31","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102749_bib32","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2019-124963","article-title":"IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)","volume":"134","author":"Kuruvilla","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102749_bib33","unstructured":"Cellosaurus MOLM-13 (CVCL_2119). 2012. https:\/\/www.cellosaurus.org\/CVCL_2119."},{"key":"10.1016\/j.xcrm.2026.102749_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-142899","article-title":"The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia","volume":"136","author":"Steinsland","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102749_bib35","unstructured":"A Phase 1\/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML). https:\/\/clinicaltrials.gov\/study\/NCT06969430. 2025."},{"key":"10.1016\/j.xcrm.2026.102749_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds","volume":"60","author":"An","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102749_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102749_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2362454","article-title":"CD20 expression regulates CD37 levels in B-cell lymphoma \u2013 implications for immunotherapies","volume":"13","author":"Bobrowicz","year":"2024","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2026.102749_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fcgamma receptors in dendritic cells and macrophages","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102749_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad025","article-title":"Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma","volume":"3","author":"Kleinau","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.xcrm.2026.102749_bib41","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102749_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102749_bib43","unstructured":"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML). 2017 https:\/\/www.clinicaltrials.astellas.com\/study\/AGS67E-15-2."},{"key":"10.1016\/j.xcrm.2026.102749_bib44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10637-011-9670-0","article-title":"Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Lapusan","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.xcrm.2026.102749_bib45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Rep."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:22:20Z","timestamp":1783074140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001667"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102749","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Debiopharm International S.A. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102749"}}